[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Timothy Chen Biography and Net Worth

Director of BeiGene

Timothy Y. Chen serves as Non-Executive Independent Director of the Company. Mr. Chen has served as the Chairman of Foxconn Industrial Internet Company, a company listed on the Shanghai Stock Exchange since June 2018. From January 2016 to March 2018, he served as the President and Chief Executive Officer of Asia Pacific Telecom and as the Corporate Vice President of Hon Hai Technology Group. He served as the President of Telstra International Group and Advisor to Telstra Chief Executive Officer from November 2012 to December 2015. He was also the Chairman of Autohome, a company listed on the NASDAQ and a director of Qingdao Haier Co., Ltd., a company listed on the Shanghai Stock Exchange. He was a Non-Executive Director on the board of Telstra Corporation Limited, a company listed on the Australian Securities Exchange between April 2012 and November 2012. Previously, Mr. Chen was a partner of a China Opportunities Fund within GL Capital Group. Mr. Chen earned an MBA Degree from the University of Chicago in August 1991 and a Master’s Degree in both computer science and mathematics from Ohio State University in June 1982.

What is Timothy Yung-Cheng Chen's net worth?: The estimated net worth of Timothy Yung-Cheng Chen is at least $602,773.64 as of June 9th, 2021. Mr. Chen owns 3,164 shares of BeiGene stock worth more than $602,774 as of November 23rd. This net worth approximation does not reflect any other investments that Mr. Chen may own. Learn More about Timothy Yung-Cheng Chen's net worth.
How do I contact Timothy Yung-Cheng Chen?: The corporate mailing address for Mr. Chen and other BeiGene executives is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. BeiGene can also be reached via phone at (345) 949-4123 and via email at [email protected]. Learn More on Timothy Yung-Cheng Chen's contact information.
Has Timothy Yung-Cheng Chen been buying or selling shares of BeiGene?: Timothy Yung-Cheng Chen has not been actively trading shares of BeiGene within the last three months. Most recently, Timothy Yung-Cheng Chen sold 3,164 shares of the business's stock in a transaction on Wednesday, June 9th. The shares were sold at an average price of $351.35, for a transaction totalling $1,111,671.40. Following the completion of the sale, the director now directly owns 3,164 shares of the company's stock, valued at $1,111,671.40. Learn More on Timothy Yung-Cheng Chen's trading history.
Who are BeiGene's active insiders?: BeiGene's insider roster includes Timothy Chen (Director), Donald Glazer (Director), Jane Huang (CMO), Chan Lee (SVP), Howard Liang (CFO), John Oyler (CEO), Corazon (Corsee) Sanders (Director), Julia Wang (CFO), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeiGene's active insiders.
Are insiders buying or selling shares of BeiGene?: During the last twelve months, insiders at the sold shares 16 times. They sold a total of 95,368 shares worth more than $16,313,435.19. The most recent insider tranaction occured on October, 8th when CEO John Oyler sold 6,175 shares worth more than $1,433,958.50. Insiders at BeiGene own 7.4% of the company. Learn More about insider trades at BeiGene.
Information on this page was last updated on 10/8/2024.

Timothy Yung-Cheng Chen Insider Trading History at BeiGene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/9/2021	Sell	3,164	$351.35	$1,111,671.40	3,164
8/11/2020	Sell	1,903	$213.04	$405,415.12	2,200
11/5/2019	Sell	3,800	$189.15	$718,770.00	4,000
8/23/2019	Sell	8,614	$144.96	$1,248,685.44

Timothy Yung-Cheng Chen Buying and Selling Activity at BeiGene

BeiGene Company Overview

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Today's Range

Now: $190.51

$189.01

$192.01

50 Day Range

MA: $212.22

$187.69

$246.04

2 Week Range

Now: $190.51

$126.97

$248.16

Volume

222,703 shs

Average Volume

265,562 shs

Market Capitalization

$18.55 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63